[go: up one dir, main page]

WO2003031981A3 - Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage - Google Patents

Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage Download PDF

Info

Publication number
WO2003031981A3
WO2003031981A3 PCT/DK2002/000665 DK0200665W WO03031981A3 WO 2003031981 A3 WO2003031981 A3 WO 2003031981A3 DK 0200665 W DK0200665 W DK 0200665W WO 03031981 A3 WO03031981 A3 WO 03031981A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit
screening
specific antibody
predicting binding
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2002/000665
Other languages
English (en)
Other versions
WO2003031981A2 (fr
Inventor
Erwin Ludo Roggen
Nina Teeres Nilsson
Steffen Ernst
Shamkant Anant Patkar
Esben Peter Friis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Priority to CA002462651A priority Critical patent/CA2462651A1/fr
Priority to EP02800546A priority patent/EP1436627A2/fr
Publication of WO2003031981A2 publication Critical patent/WO2003031981A2/fr
Publication of WO2003031981A3 publication Critical patent/WO2003031981A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à un équipement permettant de prévoir la liaison d'anticorps spécifiques à des immunogènes potentiels. Ledit équipement comprend des séquences peptidiques antigéniques renfermant moins de 26 acides aminés, lesdites séquences peptidiques antigéniques étant capables de lier des anticorps spécifiquement destinés à des déterminants antigéniques structuraux contenus sur des immunogènes potentiels. Les séquences peptidiques antigéniques sont immobilisées sur un support solide.
PCT/DK2002/000665 2001-10-05 2002-10-04 Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage Ceased WO2003031981A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002462651A CA2462651A1 (fr) 2001-10-05 2002-10-04 Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage
EP02800546A EP1436627A2 (fr) 2001-10-05 2002-10-04 Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101473 2001-10-05
DKPA200101473 2001-10-05

Publications (2)

Publication Number Publication Date
WO2003031981A2 WO2003031981A2 (fr) 2003-04-17
WO2003031981A3 true WO2003031981A3 (fr) 2004-03-04

Family

ID=8160753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000665 Ceased WO2003031981A2 (fr) 2001-10-05 2002-10-04 Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage

Country Status (3)

Country Link
EP (1) EP1436627A2 (fr)
CA (1) CA2462651A1 (fr)
WO (1) WO2003031981A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
WO1996023873A1 (fr) * 1995-02-03 1996-08-08 Novo Nordisk A/S Alleles d'amylase-alpha
US5891640A (en) * 1992-03-06 1999-04-06 N.V. Innogenetics S.A. Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays
WO1999047680A1 (fr) * 1998-03-16 1999-09-23 Alk-Abelló A/S Allergenes recombines mutants
WO2000026230A1 (fr) * 1998-10-30 2000-05-11 Novozymes A/S Variants proteiques faiblement allergenes
WO2000032626A1 (fr) * 1998-11-25 2000-06-08 Regents Of The University Of Minnesota Procedes d'utilisation de peptides d'epitopes d'agents pathogenes humains
US6210901B1 (en) * 1994-01-31 2001-04-03 Roche Diagnostics Gmbh Specific binding substances for antibodies and their use for immunoassays or vaccines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5891640A (en) * 1992-03-06 1999-04-06 N.V. Innogenetics S.A. Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays
US6210901B1 (en) * 1994-01-31 2001-04-03 Roche Diagnostics Gmbh Specific binding substances for antibodies and their use for immunoassays or vaccines
WO1996023873A1 (fr) * 1995-02-03 1996-08-08 Novo Nordisk A/S Alleles d'amylase-alpha
WO1999047680A1 (fr) * 1998-03-16 1999-09-23 Alk-Abelló A/S Allergenes recombines mutants
WO2000026230A1 (fr) * 1998-10-30 2000-05-11 Novozymes A/S Variants proteiques faiblement allergenes
WO2000032626A1 (fr) * 1998-11-25 2000-06-08 Regents Of The University Of Minnesota Procedes d'utilisation de peptides d'epitopes d'agents pathogenes humains

Also Published As

Publication number Publication date
WO2003031981A2 (fr) 2003-04-17
CA2462651A1 (fr) 2003-04-17
EP1436627A2 (fr) 2004-07-14

Similar Documents

Publication Publication Date Title
WO2002085926A3 (fr) Procede de production de series d'anticorps stables regenerables
ES2121400T3 (es) Seleccion celular positiva y positiva/negativa mediada por liberacion con peptidos.
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
WO2003029458A3 (fr) Procede pour produire des banques de proteines et selectionner des proteines a partir de ces banques
WO1995018826A3 (fr) Antigenes a ctla-8 de primates purifiee et reactifs correspondants
EP1191337A3 (fr) Essai immunologique pour la détermination du C-peptide humain ainsi qu'une trousse d'essai appropriée
WO1998027114A3 (fr) Antigenes de surface mammaliens et reactifs associes
TW200516083A (en) Methods for making dual specificity antibodies
WO2003087129A3 (fr) Peptides immunogenes et methode d'identification desdits peptides
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
EP2186884A3 (fr) Anticorps monoclonaux contre des antigènes du noyau de CHV
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
EP1114864A3 (fr) Antigènes de surface de cellules de mammifères
AU2002349344A1 (en) Microfluidic extraction method
WO2003045975A3 (fr) Immobilisation en phase solide de proteines et de peptides
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
IL154000A (en) A method that uses antibodies to diagnose arthritis
WO2002036738A3 (fr) Maturation d'affinite par selection concurrentielle
AU7960600A (en) Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit
WO2003018797A3 (fr) Procede et dispositif destines a l'expression, la purification et la detection proteiques
AU2001276916A1 (en) Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
WO1998039421A3 (fr) Proteinase mammaliennes, oxydoreductase, proteines de liaison avec gtp et reactifs correspondants
WO2003031981A3 (fr) Equipement permettant de prevoir la liaison d'un anticorps specifique a un immunogene potentiel, et methode de criblage
WO2002090989A3 (fr) Procede permettant de detecter des antigenes de globules sanguins et des anticorps diriges contre ces antigenes
EP1094080A3 (fr) Anticorps contre la DNse-gamma, sa production et utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2462651

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002800546

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002333222

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002800546

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP